← Leaderboards
Peter D Reaven
Phoenix Va Health Care System
$8,177,869
Attributed
$11,790,968
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,790,968 · 8
VA$0 · 2
By mechanism
R01$6,064,038 · 3
R24$4,497,803 · 1
R18$755,793 · 1
R21$473,334 · 2
I01$0 · 2
M01$0 · 1
Top collaborators
- Randall W Nelson4 shared
- James David Pearson4 shared
- Matthew P Buman3 shared
- Juraj Koska2 shared
- Jin Zhou2 shared
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusNon-Insulin-Dependent Diabetes MellitusEventCohortCardiovascular DiseasesGlucoseClinical ResearchFutureCardiovascular Disorder RiskBaseLipidsAtherosclerosisCardiovascular SystemLinkBlood VesselsMyocardial InfarctionStrokeRisk FactorsDiabetes Mellitus TherapyHuman SubjectPathway InteractionsGlycemic ControlMediatingGlycosylated Hemoglobin A
Grant awards (39)
Use of continuous glucose monitoring and long-term diabetes outcomes within the Veteran Affairs Health Care System$0
I01 · FY2025 · VA · contact PI
Use of continuous glucose monitoring and long-term diabetes outcomes within the Veteran Affairs Health Care System$0
I01 · FY2024 · VA · contact PI
Apolipoprotein-C Proteoforms in Dyslipidemia and Cardiovascular Disease$402,252
R01 · FY2021 · HL · contact PI
A Role for Glycemic Variation in Optimizing Management of Diabetes and Vascular Complications$127,224
R21 · FY2021 · HL
Apolipoprotein-C Proteoforms in Dyslipidemia and Cardiovascular Disease$478,718
R01 · FY2020 · HL · contact PI
Apolipoprotein-C Proteoforms in Dyslipidemia and Cardiovascular Disease$397,100
R01 · FY2020 · HL · contact PI
A Role for Glycemic Variation in Optimizing Management of Diabetes and Vascular Complications$122,816
R21 · FY2020 · HL
Role of Methionine Sulfoxide and Advanced Glycation Endproducts in Cardiovascular and Renal Complications of Type 2 Diabetes$106,147
R21 · FY2020 · HL
Apolipoprotein-C Proteoforms in Dyslipidemia and Cardiovascular Disease$457,266
R01 · FY2019 · HL · contact PI
Role of Methionine Sulfoxide and Advanced Glycation Endproducts in Cardiovascular and Renal Complications of Type 2 Diabetes$117,147
R21 · FY2019 · HL
Apolipoprotein-C Proteoforms in Dyslipidemia and Cardiovascular Disease$536,771
R01 · FY2018 · HL · contact PI
Smartphone-Based Diabetes Prevention in the VA: A Cluster-Randomized Trial$241,859
R18 · FY2018 · DK
Smartphone-Based Diabetes Prevention in the VA: A Cluster-Randomized Trial$245,152
R18 · FY2017 · DK
Smartphone-Based Diabetes Prevention in the VA: A Cluster-Randomized Trial$268,782
R18 · FY2016 · DK
Mechanisms of Dietary Lipid Induced Insulin Resistance$0
I01 · FY2015 · VA · contact PI
Team Approach to Translate Novel Biomarkers for Diabetes$1,086,558
R24 · FY2014 · DK
Mechanisms of Dietary Lipid Induced Insulin Resistance$0
I01 · FY2014 · VA · contact PI
Team Approach to Translate Novel Biomarkers for Diabetes$1,094,145
R24 · FY2013 · DK
Vascular Metabolic Memory in Type 2 Diabetes$594,871
R01 · FY2013 · HL · contact PI
Mechanisms of Dietary Lipid Induced Insulin Resistance$0
I01 · FY2013 · VA · contact PI
Team Approach to Translate Novel Biomarkers for Diabetes$1,141,528
R24 · FY2012 · DK
Vascular Metabolic Memory in Type 2 Diabetes$603,004
R01 · FY2012 · HL · contact PI
Mechanisms of Dietary Lipid Induced Insulin Resistance$0
I01 · FY2012 · VA · contact PI
Team Approach to Translate Novel Biomarkers for Diabetes$1,175,572
R24 · FY2011 · DK
Vascular Metabolic Memory in Type 2 Diabetes$637,832
R01 · FY2011 · HL · contact PI
Vascular Metabolic Memory in Type 2 Diabetes$641,550
R01 · FY2010 · HL · contact PI
Vascular Metabolic Memory in Type 2 Diabetes$639,674
R01 · FY2009 · HL · contact PI
Non-traditional Cardiovascular Risk Factors in DM type 2$225,000
R01 · FY2004 · HL
Non-traditional Cardiovascular Risk Factors in DM type 2$225,000
R01 · FY2003 · HL
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2002 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2002 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2002 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2002 · RR
Non-traditional Cardiovascular Risk Factors in DM type 2$225,000
R01 · FY2001 · HL
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2001 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2001 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR
NIASPAN IN TYPE II DIABETICS W/ DYSLIPIDEMIA$0
M01 · FY2000 · RR